ライフサイエンスコーパス: kappa opioid receptor

1 oid peptides are endogenous agonists for the kappa opioid receptor.

2 anomolar to low nanomolar K(e) values at the kappa opioid receptor.

3 and efficacy-delimited conformations of the kappa opioid receptor.

4 macology of full and partial agonists at the kappa opioid receptor.

5 lbene that functions as an antagonist of the kappa opioid receptor.

6 understanding of its role in binding to the kappa-opioid receptor.

7 ent and probes for exploring the role of the kappa-opioid receptor.

8 nuclei, structures expressing high levels of kappa opioid receptors.

9 reciable binding affinity for delta, mu, and kappa opioid receptors.

10 orphin A (Dyn A) is an endogenous ligand for kappa opioid receptors.

11 by their binding affinity at mu, delta, and kappa opioid receptors.

12 ioid receptors or singly expressed delta and kappa opioid receptors.

13 produce dynorphin, an endogenous agonist of kappa-opioid receptors.

14 onally potent agonist in cells expressing mu/kappa-opioid receptors.

15 unctional activity of human mu-, delta-, and kappa-opioid receptors.

16 es of morphine appear to be mediated through kappa-opioid receptors.

17 through a combined action at mu-, delta- and kappa-opioid receptors.

18 ty against the cloned human mu-, delta-, and kappa-opioid receptors.

19 rphin which can inhibit dopamine release via kappa-opioid receptors.

20 nregulated), hypocretin receptor 1 (Hcrtr1), kappa opioid receptor 1 (Oprk1), and transient receptor

21 alues suggests that the potent and selective kappa opioid receptors 4, 5, 13, and 14 deserve consider

22 Finally, we demonstrate that blockade of kappa-opioid receptors (500 ng nor-BNI) within the nucle

23 We previously showed that kappa-opioid receptor activation of JNK by one class of

24 ously demonstrated that mu and delta but not kappa opioid receptors affect EA anti-hyperalgesia in an

25 In addition to high kappa-opioid receptor affinity they demonstrate high sel

26 show single-digit nanomolar to subnanomolar kappa-opioid receptor affinity, full kappa agonistic act

27 rminal alpha-helix associated with decreased kappa-opioid receptor affinity.

28 Analgesia induced by a kappa opioid receptor agonist administered at the supras

29 has been found to be a potent and selective kappa opioid receptor agonist in vitro and in vivo.

30 Bath application of the kappa opioid receptor agonist U69593 decreased D2-recept

31 nd for aversion induced by thermal pain or a kappa opioid receptor agonist.

32 Salvinorin A (SA) is a kappa-opioid receptor agonist and atypical dissociative

33 ral agent with mixed opioid effects (mu- and kappa-opioid receptor agonist and delta-opioid receptor

34 ve-like (threshold-elevating) effects of the kappa-opioid receptor agonist U50,488.

35 GABA(B) agonist baclofen (1 microM) and the kappa-opioid receptor agonist U69593 [(+)-(5alpha,7alpha

36 the leaves of Salvia divinorum, is a potent kappa-opioid receptor agonist, making it an attractive s

37 uppression of phasic dopamine release by the kappa-opioid receptor agonist, salvinorin A, supporting

38 tionality on the A-ring in its activity as a kappa-opioid receptor agonist.

39 evidence for the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and

40 Kappa opioid receptor agonists inhibit VTA DA neurons th

41 the NAc, are reduced after local infusion of kappa opioid receptor agonists into the VTA.

42 tions and experimental evidence from several kappa opioid receptor agonists, we illustrate a "competi

43 lation, but not microinjection of the mu- or kappa-opioid receptor agonists in control shRNA-treated

44 were designed as conformationally restricted kappa-opioid receptor agonists restricted to the periphe

45 alogues showed sub-nanomolar potency for the kappa opioid receptor and were highly selective relative

46 gues do not show affinity for both delta and kappa opioid receptors and bind only poorly to the mu re

47 We describe the interactions between kappa opioid receptors and the dopaminergic pathways tha

48 ologous interaction between the mu, delta or kappa opioid receptors and the receptors for the chemoki

49 by their binding affinity at mu, delta, and kappa opioid receptors and their relative efficacy in th

50 ors could increase the binding of nor-BNI to kappa opioid receptors and vice versa, suggesting recipr

51 ressed by the activation of mu-, delta-, and kappa-opioid receptors and by adrenergic alpha2A recepto

52 vivo functional relevance of heteromeric mu/kappa-opioid receptors and suggests an approach to poten

53 an be rescued by the expression of the human kappa opioid receptor, and injection of human opioid rec

54 g K(i) values of 0.47 nM for both the mu and kappa opioid receptors, and 4a, having K(i) values of 0.

55 s such as the beta2-adrenergic receptor, the kappa-opioid receptor, and the parathyroid hormone recep

56 bits basal forebrain cholinergic neurons via kappa-opioid receptors, and decreases afferent excitator

57 r define the pharmacophore for this class of kappa opioid receptor antagonist and has identified new

58 cle, EA at 10 Hz plus either a mu, delta, or kappa opioid receptor antagonist did not significantly d

59 5a, KAA-1) as the first potent and selective kappa opioid receptor antagonist from the 5-(3-hydroxyph

60 (JDTic, 1) as the first potent and selective kappa opioid receptor antagonist from the trans-3,4-dime

61 receptors was the most potent and selective kappa opioid receptor antagonist identified.

62 east as potent and selective as nor-BNI as a kappa opioid receptor antagonist in the [35S]GTP-gamma-S

63 receptor-1 antagonist antalarmin but not the kappa opioid receptor antagonist JDTic.

64 benzamide (11a), a compound that showed good kappa opioid receptor antagonist properties.

65 infusion of norbinaltorphimine, a selective kappa opioid receptor antagonist, in the BLA reduced alc

66 ptor antagonist, naltrexone or the selective kappa opioid receptor antagonist, nor-binaltorphimine, b

67 identified as the first potent and selective kappa-opioid receptor antagonist from the trans-3,4-dime

68 tra-pPVT administration of OrxA+/-DynA+/-the kappa-opioid receptor antagonist nor-binaltorphimine (No

69 ce with an ultra-low-dose (0.1 ng/kg) of the kappa-opioid receptor antagonist, nor-binaltorphimine (n

70 release in VP neurons was also blocked by a kappa-opioid receptor antagonist.

71 Animal studies suggest that kappa opioid receptor antagonists (KORAn) potentially co

72 l of the analogues were potent and selective kappa opioid receptor antagonists.

73 rest in the discovery and development of new kappa opioid receptor antagonists.

74 racterize the SAR of the compound 3 class of kappa opioid receptor antagonists.

75 s from the pooled data set of delta, mu, and kappa opioid receptor antagonists.

76 terials and their use in preparing potential kappa opioid receptor antagonists.

77 hat the duration of action of small molecule kappa-opioid receptor antagonists in vivo is determined

78 Variations in OPRK1, which encodes the kappa-opioid receptor, are associated with the risk for

79 to develop a new Gi-coupled DREADD using the kappa-opioid receptor as a template (KORD) that is activ

80 ach to restrict expression of the inhibitory kappa opioid-receptor based DREADD (KORD) in vSub-->NAc

81 The pharmacological blockade of kappa-opioid receptors before the extinction trials but

82 Mu/kappa opioid-receptor blockade and activation had exagge

83 ses food intake, and the LHa contains mu and kappa opioid receptors, both of which are involved in fe

84 inhibits MCPO/SI cholinergic neurons through kappa-opioid receptors by (1) activation of a G protein-

85 ity in this series for coexpressed delta and kappa opioid receptors (CDK).

86 ppreciable selectivity for delta over mu and kappa opioid receptors (delta/mu = 80; delta/kappa > 200

87 e transmembrane helices (TMs) 7 of delta and kappa opioid receptors (deltaOR and kappaOR) that are on

88 heir in vitro efficacy at the mu, delta, and kappa opioid receptors determined and compared to JDTic

89 eir binding affinities at the mu, delta, and kappa opioid receptors determined.

90 After they are released, they activate kappa opioid receptors distributed throughout the brain

91 d mu opioid receptor (MOR) agonist and delta/kappa opioid receptor (DOR/KOR) antagonist with potent a

92 tress exposure, involvement of the dynorphin/kappa opioid receptor (DYN/KOR) system in binge-like dri

93 Animal studies indicate that the kappa-opioid receptor/dynorphin system plays an importan

94 Interestingly, a selective antagonist of kappa-opioid receptors enhanced activity of the hypocret

95 onstrated that traditional mu(1), delta, and kappa opioid receptor gene expression is not detected in

96 ablished the colocalization of mu-opioid and kappa-opioid receptor genes and OT genes at the OT-relea

97 Dynorphin, an endogenous ligand of kappa (kappa) opioid receptors, has multiple roles in the brain

98 ndular epithelial cell 1) bound to the human kappa opioid receptor (hKOPR) and promoted cell surface

99 ted protein (MAP) family, bound to the human kappa opioid receptor (hKOPR) and promoted hKOPR cell su

100 he proteins co-immunoprecipitated with human kappa-opioid receptor (hKOPR) from extracts of solubiliz

101 that interacts with the C-tail of the human kappa opioid receptor (hKOR) by yeast two-hybrid screeni

102 e present study examined the distribution of kappa opioid receptor immunoreactivity in the RVM of mal

103 imals by the expression of npr-17 or a human kappa opioid receptor in the two ASI sensory neurons, wi

104 First, Dbx1 preBotC neurons express kappa-opioid receptors in addition to mu-opioid receptor

105 A) that selectively activates heteromeric mu/kappa-opioid receptors in HEK-293 cells and induces pote

106 ere pan-agonists, binding to mu-, delta-, or kappa-opioid receptors in the low nanomolar range (2.2-3

107 ks acute analgesic tolerance to morphine and kappa opioid receptor inactivation in vivo.

108 pJNK-ir did not increase in mice lacking the kappa-opioid receptor; increased pJNK-ir returned to bas

109 ived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of bo

110 gation of bivalent ligands at mu, delta, and kappa opioid receptors is focused on the preparation of

111 The kappa-opioid receptor is a widely expressed G-protein-co

112 ral basis to salvinorin A recognition of the kappa-opioid receptor is evaluated using a combination o

113 d exhibit low nanomolar binding affinity for kappa opioid receptors (K(i) = 0.84-11 nM).

114 anterior insula with a downregulation of the kappa opioid receptor (Kappa), as well as decreased DNA

115 is an effective PAM at the mu-OR and at the kappa-opioid receptor (kappa-OR), but it is ineffective

116 respiratory drive, mood, and--in the case of kappa-opioid receptor (kappa-OR)--dysphoria and psychoto

117 Mice lacking the kappa opioid receptor (kappaOR) and adenoviral vectors o

118 The kappa opioid receptor (kappaOR) is an important target f

119 The dynorphin (DYN)-kappa opioid receptor (kappaOR) system has been implicat

120 Among the opioid receptors, the kappa-opioid receptor (kappaOR) has been gaining conside

121 Antagonists of glucocorticoid receptors and kappa opioid receptors (kappaORs) were administered at v

122 Stressful experiences potently activate kappa opioid receptors (kappaORs).

123 The kappa-opioid receptor (KOP-r) system and its endogenous

124 The present studies examined the kappa-opioid receptor (KOP-R) system in Withdrawal Seizu

125 0,488H promoted phosphorylation of the mouse kappa opioid receptor (KOPR) at residues S356, T357, T36

126 kappa-Opioid receptors (KOPr; encoded by OPRK1), and the

127 CE STATEMENT Emerging evidence suggests that kappa opioid receptor (KOR) activation can selectively m

128 We hypothesized that kappa opioid receptor (KOR) activation during chronic op

129 endogenous dynorphin opioids and subsequent kappa opioid receptor (KOR) activation.

130 r(1)]Dyn A-(1-11)NH(2) resulted in increased kappa opioid receptor (KOR) affinity for all of the line

131 y 0.5 nM) to both receptors, but also showed kappa opioid receptor (KOR) agonist activity.

132 Dual-acting kappa opioid receptor (KOR) agonist and mu opioid recept

133 Here we show that kappa opioid receptor (KOR) agonists act as anti-angioge

134 Kappa opioid receptor (KOR) agonists have the potential

135 Kappa opioid receptor (KOR) agonists produce analgesic a

136 Kappa opioid receptor (KOR) agonists show promise in ame

137 The kappa opioid receptor (KOR) and its endogenous agonist,

138 ent work has established a role for both the Kappa Opioid Receptor (KOR) and its endogenous ligand dy

139 th varying pharmacological properties at the kappa opioid receptor (KOR) and mu opioid receptor (MOR)

140 Kappa opioid receptor (KOR) antagonists are being develo

141 kappa opioid receptor (KOR) antagonists are potential ph

142 roxyphenyl) piperidine (JDTic) are selective kappa opioid receptor (KOR) antagonists having very long

143 otypical member of the receptor-inactivating kappa opioid receptor (KOR) antagonists, norbinaltorphim

144 We have studied changes in kappa opioid receptor (KOR) binding availability in vivo

145 We evaluated the occupancy of the kappa opioid receptor (KOR) by naltrexone measured with

146 mRNA of kappa opioid receptor (KOR) can be transported to nerve

147 screte regions of the NAc, activation of the kappa opioid receptor (KOR) decreases the reinforcing pr

148 ond and the third generation ones showed MOR/kappa opioid receptor (KOR) dual selectivity.

149 The mouse kappa opioid receptor (KOR) gene is constitutively expre

150 1-13) peptide (dynorphin) bound to the human kappa opioid receptor (KOR) has been determined by liqui

151 This study reveals a functional role for kappa opioid receptor (KOR) in EGF-stimulated neurite ex

152 We investigated the potential role of the kappa opioid receptor (KOR) in the therapeutic effect of

153 AtT-20 cells expressing the wild-type kappa opioid receptor (KOR) increased phospho-p38 MAPK f

154 The expression of kappa opioid receptor (KOR) is subjected to both transcr

155 The kappa opioid receptor (KOR) is widely expressed in the C

156 Kappa opioid receptor (KOR) ligands alter nociceptive re

157 as the agonist effect of beta-FNA is clearly kappa opioid receptor (KOR) mediated.

158 Activation of the dynorphin/kappa opioid receptor (KOR) system by either repeated st

159 The endogenous dynorphin-kappa opioid receptor (KOR) system encodes the dysphoric

160 Given that the kappa opioid receptor (KOR) system has been implicated i

161 lts suggest that activation of the dynorphin/kappa opioid receptor (KOR) system is likely to play a m

162 have shown that activation of the dynorphin-kappa opioid receptor (KOR) system leads to aversive, dy

163 the opioid receptors with preference for the kappa opioid receptor (KOR), and its structure-activity

164 at activation of the dynorphin receptor, the kappa opioid receptor (KOR), is required for the BDNF-me

165 Despite a growing interest in the kappa opioid receptor (KOR), KOR-selective fluorescent p

166 l kinase (JNK) by the G(i/o) protein-coupled kappa opioid receptor (KOR), mu opioid, and D2 dopamine

167 ism and that this effect is dependent on the kappa opioid receptor (KOR), specifically in the lateral

168 (d-Asp(5),Dap(8))]dynorphin A(1-11)NH2) is a kappa opioid receptor (KOR)-selective antagonist in vitr

169 is a new antagonist PET radioligand for the kappa opioid receptor (KOR).

170 ibutable to the endogenous activation of the kappa opioid receptor (KOR).

171 of Netrin-1 in translational stimulation of kappa opioid receptor (KOR).

172 show that this response is regulated by the kappa opioid receptor (KOR).

173 eceptor gene (NK3) and the Dyn receptor [the kappa opioid receptor (KOR)] gene.

174 ropeptide dynorphin, an endogenous ligand at kappa opioid receptors (KOR) that suppresses dopamine re

175 iction: dopamine, mu-opioid receptors (MOR), kappa opioid receptors (KOR), and brain-derived neurotro

176 but not in dynorphin knock-out, mice lacking kappa opioid receptors (KOR-/-) or in wild-type mice pre

177 orphin, the endogenous ligand for the kappa (kappa) opioid receptor (KOR), is thought to be involved

178 Studies have shown kappa-opioid receptor (KOR) abnormalities in addictive d

179 ioid peptide dynorphin, we microinjected the kappa-opioid receptor (KOR) agonist U50,488 directly int

180 is an apparently selective and highly potent kappa-opioid receptor (KOR) agonist.

181 tional design of highly potent and selective kappa-opioid receptor (KOR) agonists (conorphins) with e

182 rphin function, because they are mimicked by kappa-opioid receptor (KOR) agonists and attenuated by K

183 d peripherally active, potent, and selective kappa-opioid receptor (KOR) agonists comprising the ethy

184 kappa-Opioid receptor (KOR) agonists do not activate the

185 Kappa-opioid receptor (KOR) agonists have dysphoric prop

186 previously demonstrated that the spinal cord kappa-opioid receptor (KOR) and mu-opioid receptor (MOR)

187 peated swim stress caused activation of both kappa-opioid receptor (KOR) and p38 mitogen-activated pr

188 R and fluorescence spectroscopy in the human kappa-opioid receptor (KOR) and the human A2A adenosine

189 ast-fail approach evaluated the potential of kappa-opioid receptor (KOR) antagonism for treating anhe

190 ed aversive behaviors that were blocked by a kappa-opioid receptor (KOR) antagonist and absent in mic

191 Administration of the kappa-opioid receptor (KOR) antagonist JDTic (30 mg/kg,

192 Administration of a kappa-opioid receptor (KOR) antagonist reduced stress ef

193 orted anhedonia, 8 weeks of treatment with a kappa-opioid receptor (KOR) antagonist resulted in signi

194 Recent work indicates that kappa-opioid receptor (KOR) antagonists can block CRF ef

195 Our goal was to investigate changes in kappa-opioid receptor (KOR) availability in the human br

196 The kappa-opioid receptor (KOR) has been implicated in depre

197 The kappa-opioid receptor (KOR) has emerged as a promising t

198 We examined whether genetic deletion of the kappa-opioid receptor (KOR) in mice alters metabolic phy

199 Endogenous dynorphin signaling via the kappa-opioid receptor (KOR) in the nucleus accumbens (NA

200 kappa-opioid receptor (KOR) is detected pre- and postsyn

201 The kappa-opioid receptor (KOR) is implicated in various neu

202 The kappa-opioid receptor (KOR) is the primary target for th

203 evidence to suggest that drug actions at the kappa-opioid receptor (KOR) may represent a means to con

204 wild-type mice, but not in mice lacking the kappa-opioid receptor (KOR) or lacking the G-protein rec

205 YN) A-like peptide expression and heightened kappa-opioid receptor (KOR) signaling in the central nuc

206 Previously it was demonstrated that kappa-opioid receptor (KOR) signaling in the striatum pl

207 rats, increased spinal dynorphin release and kappa-opioid receptor (KOR) signaling, as well as the em

208 Activation of the dynorphin/kappa-opioid receptor (KOR) system by repeated stress ex

209 dies have demonstrated an enhanced dynorphin/kappa-opioid receptor (KOR) system following repeated co

210 The dynorphin (DYN)/kappa-opioid receptor (KOR) system has been implicated i

211 The dynorphin/kappa-opioid receptor (KOR) system has been previously i

212 data have implicated the activated dynorphin/kappa-opioid receptor (KOR) system in relation to these

213 Whereas the kappa-opioid receptor (KOR) system is known to mediate s

214 esigned to test the hypotheses that: (1) the kappa-opioid receptor (KOR) system mediates phenotypes r

215 The dynorphin (DYN)/kappa-opioid receptor (KOR) system plays a conserved rol

216 The dynorphin (DYN)/kappa-opioid receptor (KOR) system undergoes neuroadapta

217 an increasing amount of attention since the kappa-opioid receptor (KOR) was identified as its princi

218 pha-subunits (Galpha16 or Galphai2) with the kappa-opioid receptor (KOR) were examined.

219 molecular determinants for activation of the kappa-opioid receptor (KOR) were studied using a combina

220 while reducing affinity and efficacy at the kappa-opioid receptor (KOR), and (3) improving in vivo e

221 phin A (Dyn A), an endogenous agonist of the kappa-opioid receptor (KOR), directly inhibits proopiome

222 The kappa-opioid receptor (KOR)-dynorphin system has been im

223 due to MOR activation, but had no effect on kappa-opioid receptor (KOR)-mediated inhibition.

224 cholecystokinin receptor A (CCKAR), and the kappa-opioid receptor (KOR).

225 idence that DOR can form heteromers with the kappa-opioid receptor (KOR).

226 (K(i) = 390 and 23 nM, respectively) for the kappa-opioid receptor (KOR).

227 We detected mu-opioid receptor (MOR-1) and kappa-opioid receptor (KOR-1) expression and immunoreact

228 rmacological approaches were used to examine kappa-opioid receptor (KOR-1) regulation of dopamine (DA

229 Kappa-opioid receptors (KOR) are believed to be involved

230 The kappa-opioid receptors (KOR) are involved in mood disord

231 D" chemogenetic tool based on the inhibitory kappa opioid receptor (KORD) that can be used in conjunc

232 a novel inhibitory DREADD in which a mutated kappa-opioid receptor (KORD) is activated by the pharmac

233 a novel inhibitory DREADD in which a mutated kappa-opioid receptor (KORD) is activated by the pharmac

234 regulation of expression and the function of kappa opioid receptors (KORs) and its endogenous ligand

235 h affinity for mu opioid receptor (MORs) and kappa opioid receptors (KORs) and some affinity at delta

236 Kappa opioid receptors (KORs) are highly enriched within

237 sent study was designed to determine whether kappa opioid receptors (KORs) are localized to cells of

238 kappa opioid receptors (KORs) belong to the G-protein-co

239 Kappa opioid receptors (KORs) have an important role in

240 Kappa opioid receptors (KORs) have been characterized as

241 Kappa opioid receptors (KORs) have been implicated in an

242 eptides including dynorphin, which activates kappa opioid receptors (KORs) in the central and periphe

243 Here we show that blocking kappa opioid receptors (KORs) prior to forced-swim stres

244 Dynorphin, an endogenous ligand at kappa opioid receptors (KORs), produces depressive-like

245 these calcium oscillations are regulated by kappa opioid receptors (KORs).

246 is mediated through downstream activation of kappa-opioid receptors (KORs) and that activation of the

247 kappa-Opioid receptors (KORs) and their endogenous ligan

248 The kappa-opioid receptors (KORs) are implicated in several

249 Brain kappa-opioid receptors (KORs) are implicated in states o

250 Kappa-opioid receptors (KORs) are important for motivati

251 norphins and causes subsequent activation of kappa-opioid receptors (KORs) in limbic brain regions.

252 mRNA expression for prodynorphin (PDYN) and kappa-opioid receptors (KORs) in mesocorticolimbic brain

253 Activation of kappa-opioid receptors (KORs) in monoamine circuits resu

254 peptide dynorphin, which acts at presynaptic kappa-opioid receptors (KORs) on dopaminergic afferents

255 However, the effects of kappa opioid receptor ligands are distinct in males and

256 r-mediated excitotoxic inflammation; and [5] kappa-opioid receptor ligands also modulate Type-I audit

257 the durations of antagonist action of novel kappa-opioid receptor ligands and examined their efficac

258 mediated through a common nor-BNI-sensitive (kappa-opioid receptor-like) pathway.

259 revious research has demonstrated a role for kappa opioid receptor-mediated signaling in escalated al

260 , and more specifically, enhances delta- and kappa-opioid-receptor-mediated hypoalgesia and attenuate

261 the concomitant activation of spinal mu- and kappa-opioid receptors (MOR and KOR, respectively).

262 t upon intact opioid receptor signaling with kappa opioid receptors more involved than mu and delta o

263 led to significantly decreased mu, delta and kappa opioid receptor mRNA expression as analyzed by qua

264 exposure alters the expression of mu- and/or kappa-opioid receptor mRNA or pro-opioimelanocortin (POM

265 CX3CL1/fractalkine receptor and mu, delta or kappa opioid receptors occurs in the periaqueductal grey

266 more selectively relative to mixed delta and kappa opioid receptors or singly expressed delta and kap

267 of the vmPFC, and intra-vmPFC stimulation of kappa-opioid receptors or blockade of 5-HT2A (5-hydroxyt

268 Brain kappa-opioid receptors (ORs) may be involved in several

269 micro and delta opioid receptor antagonist, kappa opioid receptor partial agonist that has recently

270 To characterize delta- and kappa-opioid receptor phenotypes, bivalent ligands (KDAN

271 s of alpha2A adrenergic and mu-, delta-, and kappa-opioid receptors reinstated hyperalgesia during re

272 himine, an antagonist for dynorphin-targeted kappa-opioid receptor, rescued memory in old WT mice.

273 atios of 103- and 132-fold versus the mu and kappa opioid receptors, respectively.

274 as established that stably expressed the rat kappa-opioid receptor (rKOR) with a FLAG epitope at the

275 loring constraining aromatic residues in the kappa opioid receptor selective antagonist arodyn (Ac[Ph

276 neither compound showed the high potency and kappa opioid receptor selectivity of JDTic.

277 the histologic evidence suggesting abnormal kappa opioid receptor signaling in schizophrenia.

278 Here, we show that kappa opioid receptor signaling in the bed nucleus of th

279 ermined the impact of modulating both mu and kappa opioid receptor signaling using the mixed agonist/

280 such as morphine in that it mediates potent kappa opioid receptor signaling yet leads to less recept

281 kappa opioid receptors, unmasking inhibitory kappa opioid receptor signaling, and converting endogeno

282 Our findings establish a role of dynorphin kappa-opioid receptor signaling in fear extinction.

283 by both the ebb and flow of spinal dynorphin/kappa-opioid receptor signaling over the estrous cycle,

284 tor antagonist naloxone and by the selective kappa-opioid receptor subtype antagonist nor-BNI (nor-Bi

285 uperfamily that also includes mu, delta, and kappa opioid receptor subtypes (MOR, DOR, and KOR, respe

286 our maps corresponding to the delta, mu, and kappa opioid receptor subtypes reflected the characteris

287 phore formation for wild-type mu, delta, and kappa opioid receptors suggest that these conserved resi

288 It is well known that activation of the kappa opioid receptor system modulates negative affect a

289 ction for the dysphoric effects of dynorphin-kappa-opioid receptor system activation during stress-ev

290 the stress circuits, including the dynorphin/kappa-opioid receptor system, modulates the rewarding ef

291 pherally restricted and selective agonist of kappa opioid receptors that are considered to be importa

292 dynorphin, which in turn acts on presynaptic kappa-opioid receptors to inhibit glutamate release.

293 Using mouse and human recombinant kappa opioid receptors transfected into a host cell, two

294 sing a G-protein coupled receptor, the human kappa opioid receptor type 1 (hKOR1).

295 ling by endogenous GM1-sensitized excitatory kappa opioid receptors, unmasking inhibitory kappa opioi

296 JNK-mediated receptor inactivation of the kappa-opioid receptor was evident in both agonist-stimul

297 prises three members, the micro-, delta- and kappa-opioid receptors, which respond to classical opioi

298 We first show that peripheral blockade of kappa-opioid receptors with the antagonist norbinaltorph

299 Thus, kappa-opioid receptors within the NAc shell mediate aver

300 Blockade of kappa-opioid receptors within the ventral pallidum or mu